A breakthrough drug for stage four pancreatic cancer is now available through an Extended Access Program at Intermountain Health. Dr. Mark Lewis, director of gastrointestinal oncology, reports that the medication, daraxonrasib, shows significant promise for patients facing one of the most difficult cancer diagnoses. Trials indicate the drug has the potential to double life expectancy compared to current standard chemotherapy treatments.
Pancreatic cancer remains a serious health challenge because it is often discovered after it has spread or become inoperable. Standard treatment usually involves intravenous chemotherapy every two weeks, which can be difficult for patients to manage long-term. Daraxonrasib targets the KRAS mutation directly, which is common in many pancreatic cancer cases. By shutting down the growth signals caused by this mutation, the drug aims to stop the spread of the disease more effectively than previous options.
While the drug is not a cure, it offers a new way to control the disease. Intermountain Health currently has nine patients waiting for the first shipments of the medication. The program is part of a broader push to provide early access to new therapies before full FDA approval. Doctors emphasize that this medication represents a shift toward precision treatment for patients who previously had few alternatives.
Patients using this new therapy are report being optimistic, though realistic about the potential side effects. Those symptoms can include rash, diarrhea, and mouth sores. Medical professionals at institutions like the Huntsman Cancer Institute and Utah Cancer Specialists are now helping manage the distribution of the drug to ensure patients can access it regardless of their location. An application for formal FDA approval was submitted in late July, with a decision expected in the coming weeks.